- Telehealth Visits
- Insurance plan information
Aimee W. Kao, MD, PhD
Neurology • Memory and Cognitive Disorders Neurology- Telehealth Visits
- Insurance plan information
Aimee W. Kao, MD, PhD
Neurology • Memory and Cognitive Disorders Neurology- Telehealth Visits
- Insurance plan information
On this page
About me
Dr. Aimee Kao is an expert in the diagnosis and treatment of age-related cognitive conditions such as Alzheimer's disease, Lewy body disease and frontotemporal lobar degeneration. Kao's research uses model organisms such as the roundworm C. elegans to understand the basic mechanisms of neurodegenerative diseases.
Kao's research is funded by the National Institutes of Health.
Kao received her bachelor of science degree from Brown University and her medical and doctoral degrees from the University of Iowa Carver College of Medicine. She completed her internship at the Beth Israel Deaconess Medical Center and her neurology residency at UCSF, where she was chief resident. She has fellowship training in behavioral neurology and molecular genetics. Kao joined the UCSF faculty in 2007.
Education & training
Board certification
- Neurology, American Board of Psychiatry and Neurology
Fellowship
- Behavioral Neurology, UCSF Graduate Medical Education
Residency
- Neurology, UCSF Graduate Medical Education
Internship
- Beth Israel Deaconess Medical Center GME
Degree
- MD, University of Iowa
My expertise
Locations
Clinical Trials query: q=health_gateway_id_ss%3A%28%22825%22%29+AND+status_s%3A%28%22Recruiting%22%29&rows=4&sort=date_published+desc&fq=content_type%3A%22Clinical+Trial%22
Puiblications query: q=health_gateway_id_ss%3A%28%22825%22%29&rows=4&sort=date_published+desc&fq=content_type%3A%22Publication%22
For informational purposes only, a link to the federal Centers for Medicare and Medicaid Services (CMS) Open Payments web page is provided here. The federal Physician Payments Sunshine Act requires that detailed information about payment and other payments of value worth over ten dollars ($10) from manufacturers of drugs, medical devices, and biologics to physicians and teaching hospitals be made available to the public.